Chi Sheng Pharma & Biotech Co., Ltd. AI Stock Analysis
Chi Sheng Pharma & Biotech Co., Ltd. (4111) AI Stock Analysis
Chi Sheng Pharma & Biotech Co., Ltd.
(TPEx:4111)
The overall score of 72 reflects a company with strong fundamentals and attractive valuation offset by weak near-term technical momentum. The financial performance is the standout strength, driven by a powerful turnaround in revenue, profitability, and cash flow, supported by a pristine balance sheet. The low P/E of 9x and high 4.6% dividend yield add significant appeal. However, the stock is under clear selling pressure, trading below key moving averages with negative MACD and low RSI, which weighs on the score. The divergence between strong fundamentals and weak technicals suggests the market may be pricing in historical cyclicality risks not yet evident in current results.
Chi Sheng Pharma & Biotech Co., Ltd. (4111) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 1.71B
- Dividend Yield
- 4.56%
- Average Volume (3M)
- 64.01K
- Price to Earnings (P/E)
- 9.2
- Beta (1Y)
- 0.15
- Revenue Growth
- 5.33%
- EPS Growth
- 13.75%
- Country
- TW
- Employees
- 80
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Instruments & Supplies
Chi Sheng Pharma & Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Chi Sheng Pharma & Biotech Co., Ltd. is a Taiwan-based company actively engaged in the development, production, distribution, and international trade of a diverse range of products. Operating across both domestic and global markets, the company speci...
Chi Sheng Pharma & Biotech Co., Ltd. Financial Statement Overview
Summary
Chi Sheng Pharma exhibits a strong financial resurgence with synchronized improvements across all statements. Revenue grew 18%, net profit margins more than doubled to ~12%, and the balance sheet is a fortress with a debt-to-equity ratio of just 0.04. Cash flow generation has transformed dramatically, with free cash flow surging over 140% and covering 77% of net income. The primary risk is historical cyclicality and cash flow volatility, but current performance is excellent.
Income Statement
78PositiveBalance Sheet
88Very PositiveCash Flow
85Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.42B | 1.38B | 1.17B | 1.06B | 1.14B | 1.02B |
| Gross Profit | 533.27M | 507.61M | 397.18M | 343.10M | 422.51M | 356.58M |
| EBITDA | 287.29M | 271.75M | 204.56M | 150.75M | 236.69M | 211.94M |
| Net Income | 189.06M | 164.28M | 110.63M | 68.67M | 154.01M | 80.75M |
Balance Sheet | ||||||
| Total Assets | 2.04B | 1.94B | 1.75B | 1.77B | 1.80B | 1.66B |
| Cash, Cash Equivalents and Short-Term Investments | 472.29M | 443.91M | 336.19M | 381.05M | 456.25M | 252.27M |
| Total Debt | 44.98M | 48.77M | 185.94M | 122.90M | 290.38M | 292.20M |
| Total Liabilities | 634.64M | 557.04M | 475.08M | 547.04M | 578.38M | 559.04M |
| Stockholders Equity | 1.40B | 1.38B | 1.27B | 1.22B | 1.22B | 1.10B |
Cash Flow | ||||||
| Free Cash Flow | 220.81M | 315.19M | 127.98M | -26.98M | 109.00M | -126.18M |
| Operating Cash Flow | 307.65M | 409.05M | 213.20M | 74.52M | 214.86M | 139.33M |
| Investing Cash Flow | -88.41M | -97.17M | -86.31M | -76.61M | 63.24M | -289.02M |
| Financing Cash Flow | -69.79M | -204.17M | -171.75M | -73.11M | -74.88M | 66.68M |
Chi Sheng Pharma & Biotech Co., Ltd. Peers Comparison
Overall Rating
- TW:411172Outperform
TW:415369Neutral
TW:129467Neutral
TW:655847Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TW:4111 | 72Outperform | TWD 1.71B | 9.16 | ― | 4.56% | 5.33% | 13.75% |
| TW:4153 | 69Neutral | TWD 1.74B | 15.93 | ― | 6.48% | 9.73% | 36.89% |
| TW:1294 | 67Neutral | TWD 1.62B | 11.43 | ― | 6.70% | 20.43% | 4.47% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| TW:6558 | 47Neutral | TWD 1.81B | -10.57 | ― | 1.55% | -10.07% | -349.71% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:4111 | Chi Sheng Pharma & Biotech Co., Ltd. | 28.60 | -0.10 | -0.36% | |
| TW:1294 | Hantech Bio-Technology Co., Ltd. | 44.05 | -14.81 | -25.16% | |
| TW:4153 | Diva Laboratories, Ltd. | 30.35 | -2.30 | -7.04% | |
| TW:6558 | SYNergy ScienTech Corp. | 19.30 | -18.20 | -48.53% | |
| TW:6659 | Timing Pharmaceutical Co. Ltd. | 19.35 | -20.61 | -51.57% | |
| TW:6917 | Andros Pharmaceuticals Co., Ltd. | 31.90 | 7.80 | 32.37% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 09, 2026